Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
By J. Reubi, J. Schär, B. Waser, S. Wenger, A. Heppeler, J. Schmitt, H. Mäcke. European Journal of Nuclear Medicine, 2000
1,074 citations recorded by the source corpus.
Subfields: Epidemiology, Neurology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/264ebbe6eb04432af0fa425410917e7151d545e7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Kwekkeboom
- W. D. de Herder
- B. Kam
- C. van Eijck
- P. Kooij
- E. Krenning
- J. Teunissen
- R. Feelders
Citations in the corpus
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours (2013, neutral): “6 nM), but lower affinities for sstr5 (IC50 393±84 nM) and sstr3 (IC50 880±324 nM) [3].”
- Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. (2005, background): “The somatostatin analog [DOTA,Tyr(3)]octreotate has a nine-fold higher affinity for the somatostatin receptor subtype 2 compared with [DOTA,Tyr(3)]octreotide in vitro.(12) Also, labeled with the beta- and gamma-emitting radionuclide (177)Lu, this compound was shown to be successful in terms of tumor”
- Peptide receptors as molecular targets for cancer diagnosis and therapy. (2003, background): “2) markedly improved sst2 binding affinity (342) and in vivo tumor imaging (345).”